Skip to content
About
Our Mission
The challenge
Deliberables
Structure
Core Group
Management Committee
Working Groups
WG1: Tools for NRF2 research
WG2: Pharmacological regulation and drugs
WG3: Translational medicine
WG4. Economic Exploitation
WG5: Outreach and dissemination
Events
Scientific Meetings
Webinars
Training Schools
Open Days
Podcasts
News
Newsletters
Special Issues
Other news
Projects
Dissemination
Co-authored Action publications
Collaborative publications
Open Days
About
Our Mission
The challenge
Deliberables
Structure
Core Group
Management Committee
Working Groups
WG1: Tools for NRF2 research
WG2: Pharmacological regulation and drugs
WG3: Translational medicine
WG4. Economic Exploitation
WG5: Outreach and dissemination
Events
Scientific Meetings
Webinars
Training Schools
Open Days
Podcasts
News
Newsletters
Special Issues
Other news
Projects
Dissemination
Co-authored Action publications
Collaborative publications
Open Days
Intranet
Deliberables
Biobank Dataset by Pathology
Technologic Platform with Databases Related to NRF2, Including Advanced Technologies and Bioinformatics Tools
Inventory of New and Repurposed NRF2-Targeted Drugs with Strong Evidence of Therapeutic Benefit in Preclinical and Clinical Trials
Registry of Superior NRF2-Related Cellular and Animal Models for the Study of NRF2 in Several Non-Communicable Diseases
Report on Biochemical Biomarkers of NRF2 Activity, Including Transcripts, Proteins and Metabolites
Database of Genetic Polymorphisms Related to the NRF2 Coding Gene (NFE2L2) and the Antioxidant Response Elements of Selected NRF2- Target Genes with Known Impact on Pathology
Panel of Somatic Mutations in the KEAP1/NRF2 System in Cancer, Including Non-Small Cell Lung Carcinoma
Reports on the Engagement of Current and New SMEs, Including Consulting and Biopharma-Funded Collaborations
Public Disclosure of Procedures and Guidelines, Lead Drugs, Biomarkers, and Other Technologic Outcomes
Report of the First Industry Showcase on “Transcription Factor NRF2: New Opportunities for Pharmaceutical Innovations in Chronic Diseases” (Athens, 8–9 February 2024)
Reports on Participation in Social Media and Other Events; Organization of the Yearly “BenBedPhar Open Day”
Panel of Blood-Based Biomarkers for Clinical Monitoring of Non- Communicable Diseases (NCDs) and the Response of NCD Patients to NRF2-Targeted Therapy, Including the Design of a Clinically Relevant Biochip
Documentation for Future Clinical Trials on NRF2-Targeted Therapeutics in Selected Non-Communicable Diseases, Including Steatohepatitis and Cirrhosis
Report of the Second Industry Showcase on “Unlocking NRF2 Research for Future Clinical Therapies” (Rome, 20–21 February 2025)
Toolbox of Customized Reagents Including Antibodies, Oligonucleotides for qRT-PCR, Plasmids, Lentiviral Vectors, shRNA, and Related Molecular Tools
Critical report of current guidelines, standardized procedures and protocols for the study of the role of NRF2 in physiology and pathology of NCDs
Report of the third industry showcase on "Transcription factor NRF2: New opportunities for pharmaceutical innovations in chronic diseases"
